Valeant Pharmaceuticals (VRX) PT, Estimates Raised at Jefferies on Strong Q3
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Valeant Pharma (VRX) Reports Unsurprising Results Ahead of Dec. Meeting - FBR Capital
October 20, 2014 2:58 PM EDTFBR Capital affirms Valeant Pharma (NYSE: VRX) at Outperform with a price target of $148 following Q3 results reported today.
Analyst William Tanner noted the following key points from the quarter:3Q14 results what Valeant needed to show ahead of Special Meeting vote. Likely facing another attack from Allergan, we believe 3Q14 results may be more challenging to spin as evidence that the company's fundamentals are not strong and that the business model is flawed. One important general disclosure was that growth was driven more by volume than price, undercutting a potential argument... More
Valeant Pharma (VRX) Reports Q3 EPS of $2.11
October 20, 2014 7:03 AM EDTValeant Pharma (NYSE: VRX) reported Q3 EPS of $2.11, versus $1.43 reported last year. Revenue for the quarter came in at $2.06 billion, versus $1.54 billion reported last year.
Analysts were looking for EPS of $1.99.
Valeant sees FY14 cash EPS of $8.22 to $8.32 and Q4 EPS from $2.45... More
